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Absolute Risk Reduction Due
to Statin Use According to Sex
I would like to thank Dr. Mosca for her insightful editorial (1) on
our publication detailing a meta-analysis of the effects of statin use
in women and men (2) and for highlighting the importance of
reduction in absolute risk, particularly in primary prevention. She
also raised the issues of cost and adverse events in this population.
We performed an additional meta-analysis to examine absolute
risk reduction (ARR).
In women, the ARR of the primary endpoint was statistically
significant in primary prevention trials (0.7% [95% confidence
interval (CI): 0.3 to 1.0]; p  0.0004) and more pronounced
(4-fold) in secondary prevention trials (2.8% [95% CI: 1.5 to 4.2];
p  0.0001). The corresponding number needed to treat over a
4-year period was 148 for primary prevention and 36 for secondary
prevention. In men, the ARR of the primary endpoint was also
statistically significant in primary prevention trials (2.3% [95% CI:
1.1 to 3.4]; p  0.0001) and more pronounced in secondaryprevention trials (3.4% [95% CI: 2.0 to 4.7]; p  0.0001). The
corresponding number needed to treat over a 4-year period was 43
for primary prevention and 29 for secondary prevention.
We do not have sufficient data to perform cost-effectiveness
analyses. However, with the availability of high-potency generic
statins, the cost of medication will continue to decrease. Because
there were only 2 studies reporting sex-specific adverse effects, we
are not able to make firm statements about their adverse-effect
profile specific to women. However, their widespread use in both
men and women suggests that they are typically well tolerated. We
agree with Dr. Mosca on the importance of enrolling more women
in clinical trials and that sex-specific data should be included in the
corresponding publications.
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